Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Specific virus can interact with mutation in host's genes to trigger diseases: Scientists

Scientists have shown that a specific virus can interact with a mutation in the host's genes to trigger disease. The observation may help explain why many people with disease risk genes do not actually develop disease.

25 Jun 2010

Surgical care improvement measures associated with lower probability of postoperative infection: JAMA

An analysis of data on adherence to surgical care improvement measures finds that when analyzed as a composite infection-prevention score, the improvement measures were associated with a lower probability of postoperative infection. However, adherence to individual measures - the format of publicly reported performance data - was not associated with a significantly lower risk of infection, according to a study in the June 23/30 issue of JAMA.

25 Jun 2010

Study examines relationship between SCIP measures and postoperative infection

A study by investigators at Case Western Reserve University School of Medicine published in this week's issue of JAMA found that public hospital comparison data reported by the U.S. Department of Health and Human Services does not accurately correlate with a patient's risk for surgical postoperative infection.

24 Jun 2010

Aradigm announces $5 million private placement

Aradigm Corporation today announced that it has entered into a definitive agreement for the sale of common stock and warrants to three existing shareholders and one new investor in a private placement for aggregate gross proceeds of approximately $5 million. The closing of the private placement is subject to the satisfaction of customary closing conditions.

21 Jun 2010

ViroPharma provides update on recent progress in Cinryze manufacturing expansion activities

ViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing line and increasing the amount of drug supply available to patients suffering from hereditary angioedema, or HAE.

21 Jun 2010

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.

19 Jun 2010

LWW sponsors symposium on wound care

The 25th Anniversary Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing will be held September 30-October 3, 2010, at the Gaylord Palms Hotel and Convention Center in Kissimee, FL. The symposium is sponsored by Lippincott Williams & Wilkins (LWW), part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

17 Jun 2010

Scientists find antibiotic-resistant bacteria in seven species of sharks and redfish

Scientists have found antibiotic-resistant bacteria in seven species of sharks and redfish captured in waters off Belize, Florida, Louisiana and Massachusetts. Most of these wild, free-swimming fish harbored several drug-resistant bacterial strains.

17 Jun 2010

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

This bacterium, Escherichia coli K1, is the most common cause of meningitis in premature infants and the second most common cause of the disease in newborns. "The ineffectiveness of antibiotics in treating newborns with meningitis and the emergence of antibiotic-resistant strains of bacteria require new strategies," explains Nemani V. Prasadarao, PhD, associate professor of infectious disease at Childrens Hospital Los Angeles.

17 Jun 2010

Daily use of probiotics reduces VAP in critically ill patients: New research

Daily use of probiotics reduced ventilator-associated pneumonia in critically ill patients by almost half, according to new research from Creighton University School of Medicine in Omaha, Nebraska.

17 Jun 2010

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

Identification of a key player in a signaling pathway involved in the development of melanoma - the deadliest form of skin cancer - may offer hope for new targeted melanoma therapies.

16 Jun 2010

Anacor's AN3365 novel systemic antibiotic achieves proof of concept

Anacor Pharmaceuticals today announced that a Joint Research Committee, composed of both GlaxoSmithKline (GSK) and Anacor employees, has determined that AN3365, a novel systemic antibiotic derived from Anacor's boron chemistry platform, has achieved proof of concept as defined under the collaboration agreement between GSK and Anacor.

15 Jun 2010

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

Anacor Pharmaceuticals today announced positive clinical trial results for its lead phosphodiesterase-4 inhibitor, AN2728, a novel topical anti-inflammatory compound derived from Anacor's boron chemistry platform. These results were obtained from a multi-center, Phase 2b, randomized, double-blind, dose-ranging, bilateral trial comparing AN2728 ointment, 0.5% and 2.0%, applied once or twice daily, to vehicle in 145 patients with mild-to-moderate plaque-type psoriasis.

15 Jun 2010

SIRS-Lab, Analytik Jena partner in molecular sepsis diagnostics

SIRS-Lab GmbH and Analytik Jena AG, also based in Jena, will be strengthened by working together in the field of molecular sepsis diagnostics. As part of this cooperation, Analytik Jena subsidiary AJ Innuscreen GmbH will provide the partner with a platform for automated isolation of nucleic acids with the associated reagent system worth almost half a million euro.

15 Jun 2010

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

Oragenics, Inc., a biopharmaceutical company, announced today that the National Science Foundation has awarded the Company an additional $500,000 in funds to support the previously awarded SBIR Phase II grant for the Company's DPOLT Lantibiotic Synthesis Platform.

14 Jun 2010

PolyMedix awarded $150,000 grant to support development of antimicrobial sutures to reduce SSIs

A new discovery may help curb surgical site infections through the use of a novel antibiotic agent that can be incorporated into sutures. SSIs are the third most common hospital-acquired infection and may be associated with severe morbidity and mortality. Since more than 60% of SSIs occur in the area of the incision, the use of sutures coated with an antibacterial agent called PolyCides, created by Radnor, PA-based PolyMedix Inc., may reduce infection rates.

14 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

Anti-infectives could circumvent the problem of antibiotic resistance

For a successful infection, bacteria must outwit the immune system of the host. To this aim, they deliver so-called virulence factors through a transport channel located in the bacterial membrane.

14 Jun 2010

Otonomy completes $10 million Series A financing with Avalon Ventures

Otonomy, Inc. announced today that it has completed a $10 million Series A financing with Avalon Ventures. Proceeds from the financing will be used to support the ongoing clinical trial for OTO-104 in Meniere's disease, initiate IND-enabling studies for OTO-203, and continue early-stage development of a third program.

11 Jun 2010

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

Cubist Pharmaceuticals, Inc. today announced that it will oppose a motion filed by the Teva defendants to amend their answer to add a new defense in the patent litigation between Cubist and Teva pending in the US District Court for the District of Delaware. A motion for leave to amend the answer is a request to be permitted to add a new allegation. The Teva defendants seek leave to amend their answer to allege that US Patent Nos. 6,468,967 and 6,852,689 are unenforceable due to inequitable conduct.

11 Jun 2010

Antibiotic News and Research

Further Reading

Specific virus can interact with mutation in host's genes to trigger diseases: Scientists

Surgical care improvement measures associated with lower probability of postoperative infection: JAMA

Study examines relationship between SCIP measures and postoperative infection

Aradigm announces $5 million private placement

ViroPharma provides update on recent progress in Cinryze manufacturing expansion activities

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

LWW sponsors symposium on wound care

Scientists find antibiotic-resistant bacteria in seven species of sharks and redfish

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

Daily use of probiotics reduces VAP in critically ill patients: New research

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

Anacor's AN3365 novel systemic antibiotic achieves proof of concept

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

SIRS-Lab, Analytik Jena partner in molecular sepsis diagnostics

Oragenics awarded additional $500,000 to further development of MU 1140, DPOLT antibiotics platform

PolyMedix awarded $150,000 grant to support development of antimicrobial sutures to reduce SSIs

Olfactory function tests could help in treating patient in early stages of PD

Anti-infectives could circumvent the problem of antibiotic resistance

Otonomy completes $10 million Series A financing with Avalon Ventures

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News